CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE1831, an Allogeneic Anti-CD20 Antibody-Conjugated Gamma Delta T-cell Therapy, in Adult Subjects With Relapsed/Refractory CD20-expressing B-cell Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05653271
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:28.705433+00:00
Published At: 2025-08-11T00:00:00+00:00
Record Updated At: 2025-08-11
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["B-cell Lymphoma", "Non Hodgkin Lymphoma", "DLBCL", "Primary Mediastinal Large B Cell Lymphoma", "Marginal Zone Lymphoma", "Follicular Lymphoma", "Burkitt Lymphoma", "High-grade B-cell Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-08-11"
protocolSection.identificationModule.nctId: "NCT05653271"
protocolSection.identificationModule.officialTitle: "A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE1831, an Allogeneic Anti-CD20 Antibody-Conjugated Gamma Delta T-cell Therapy, in Adult Subjects With Relapsed/Refractory CD20-expressing B-cell Malignancies"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.